Suven Life Sciences announced the grant of one (1) product patent from Canada (2957494) and one (1) product patent from Sri Lanka (14928) corresponding to the New Chemical Entity for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through
2034 and 2026 respectively.
The granted claims of the patents include the class of selective H3 and 5-HT6 compounds respectively and are being developed as therapeutic agents for neurodegenerative disorders such as Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia and sleep disorders like Narcolepsy etc.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
